Expression of cyclins D1, D2 and D3 and Ki-67 in human leukemia

Leukemia and Lymphoma

Volumn 46, Issue 11, 2005, Pages 1605-1612

  Jaroslav, Polák ^a   Martina, Hradcová ^a   Jiří, Schwarz ^a   Hana, Klamová ^a   Petr, Stöckbauer ^a   Tomáš, Kozák ^b   Julius, Müller ^c   Cedrik, Haškovec ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

CLL; CML; Cyclin D1; D2; D3; Ki 67; Leukemia; Real time PCR

Indexed keywords

CD19 ANTIGEN; CYCLIN D1; CYCLIN D2; CYCLIN D3; KI 67 ANTIGEN; MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW CELL; CELL CYCLE; CELL PROLIFERATION; CHRONIC GRANULOCYTIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; LEUKOCYTE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACUTE DISEASE; CELL PROLIFERATION; CYCLIN D1; CYCLINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 28244483238     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500215100     Document Type: Article

References (42)

1. Lukas J, Jadayel D, Bartkova J, Nacheva E, Dyer MJ, Strauss M et al. BCL-1/cyclin D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation. Oncogene 1994;9:2159-2167.
2. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear-protein required for cell-cycle progression in G(1). Genes Dev 1993;7:812-821.
3. Won KA, Xiong Y, Beach D, Gilman MZ. Growth-Regulated expression of D-type cyclin genes in human-diploid fibroblasts. Proc Natl Acad Sci USA 1992;89:9910-9914.
4. Hirose M, Shimizu E, Nakanishi H, Shinohara A, Sone S, Kuroda Y. Expression level of G1-cyclins and cell proliferation in human cultured leukemia/lymphoma cell lines. Int J Oncol 1998;12:841-846.
5. Kohno T, Yoshida S, Bessho M. Accelerated entry into S phase associated with up-regulation of cyclin D1 as a mechanism for granulocyte colony-stimulating factor (GCSF)-induced apoptosis of murine myeloid leukemia cells. Leuk Res 1998;22:257-263.
6. Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997;57:1634-1637.
7. Akervall JA, Michalides RJ, Mineta H, Balm A, Borg A, Dictor MR et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 1997;79:380-389.
8. Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994;84:2726-2732.
9. Ott MM, Bartkova J, Bartek J, Durr A, Fischer L, Ott G et al. Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity. Blood 1997;90:3154-3159.
10. Soverini S, Martinelli G, Cavo M. Cyclin D1 expression in multiple myeloma: a pathogenetic role besides the prognostic relevance? - response. Blood 2003;102:4246.
11. Soverini S, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 2003;102:1588-1594.
12. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ et al. Myeloma and the t(11;14) (q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002;99:3735-3741.
13. Hedberg Y, Davoodi E, Roos G, Ljungberg B, Landberg G. Cyclin-D1 expression in human renal-cell carcinoma. Int J Cancer 1999;84:268-272.
14. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analyt Biochem 1987;162:156-159.
15. Haskovec C, Ponzetto C, Polak J, Maritano D, Zemanova Z, Serra A et al. P230 BCR/ABL protein may be associated with an acute leukaemia phenotype. Br J Haematol 1998;103:1104-1108.
16. Uchimaru K, Taniguchi T, Yoshikawa M, Asano S, Arnold A, Fujita T et al. Detection of cyclin D1 (bcl-1, PRAD1) overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t (11;14) (q13;q32)-bearing B-cell malignancies and/or mantle cell lymphoma. Blood 1997;89:965-974.
17. Pallisgaard N, Clausen N, Schroder H, Hokland P. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer 1999;26:355-365.
18. Delmer A, Ajchenbaum CF, Tang R, Ramond S, Faussat AM, Marie JP et al. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 1995;85:2870-2876.
19. Sola B, Roue G, Duquesne F, Avet-Loiseau H, Macro M, Salaun V et al. Expression of cyclins D-type in B-chronic lymphoproliferative disorders. Leukemia 2000;14:1318-1319.
20. Suzuki R, Kuroda H, Komatsu H, Hosokawa Y, Kagami Y, Ogura M et al. Selective usage of D-type cyclins in lymphoid malignancies. Leukemia 1999;13:1335-1342.
21. Bosch F, Campo E, Jares P, Pittaluga S, Munoz J, Nayach I et al. Increased expression of the PRAD-1/CCND1 gene in hairy cell leukaemia. Br J Haematol 1995;91:1025-1030.
22. Weisenburger DD, Armitage JO. Mantle cell lymphoma - an entity comes of age. Blood 1996;87:4483-4494.
23. Elenitoba-Johnson KSJ, Bohling SD, Jenson SD, Lin ZS, Monnin KA, Lim MS. Fluorescence PCR quantification of cyclin D1 expression. J Mol Diagnost 2002;4:90-96.
24. Koiso H, Tsukamoto N, Miyawaki S, Shinonome S, Nojima Y, Karasawa M. Quantitative analysis of Cyclin D1 and CD23 expression in mantle cell lymphoma and B-chronic lymphocytic leukemia. Leuk Res 2002;26:809-815.
25. Ullmannová V, Stöckbauer P, Hradcová M, Souček J, Haškovec C. Relationship between cyclin D1 and p21 (Waf1/Cip1) during differentiation of human myeloid leukemia cell lines. Leuk Res 2003;27:1115-1123.
26. Li Z, Hromchak R, Bloch A. Differential expression of proteins regulating cell cycle progression in growth versus differentiation. Biochim Biophys Acta 1997;1356:149-159.
27. Atadja P, Wong H, Veillete C, Riabowol K. Overexpression of cyclin D1 blocks proliferation of normal diploid fibroblasts. Exp Cell Res 1995;217:205-216.
28. Fukami-Kobayashi J, Mitsui Y. Cyclin D1 inhibits cell proliferation through binding to PCNA and Cdk2. Exp Cell Res 1999;246:338-347.
29. Sauerbrey A, Hafer R, Zintl F, Volm M. Analysis of cyclin D1 in de novo and relapsed childhood acute lymphoblastic leukemia. Anticancer Res 1999;19:645-649.
30. Yatabe Y, Suzuki R, Tobinai K, Matsuno Y, Ichinohasama R, Okamoto M et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 2000;95:2253-2261.
31. Volm M, Koomagi R, Stammler G, Rittgen W, Zintl F, Sauerbrey A. Prognostic implications of cyclins (D1, E, A), cyclin-dependent kinases (CDK2, CDK4) and tumor-suppressor genes (pRB, p16INK4A) in childhood acute lymphoblastic leukemia. Int J Cancer 1997;74:508-512.
32. Levy V, Ugo V, Delmer A, Tang R, Ramond S, Perrot JY et al. Cyclin D1 overexpression allows identification of an aggressive subset of leukemic lymphoproliferative disorder. Leukemia 1999;13:1343-1351.
33. Ravandi-Kashani F, O'Brien S, Manshouri T, Lerner S, Sim S, Dodd K et al. Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia. Leuk Res 2000;24:469-474.
34. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, Bataille R et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002;100:1579-1583.
35. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996;69:92-99.
36. Wong KF. 11q13 is a cytogenetically promiscuous site in hematologic malignancies. Cancer Genet Cytogenet 1999;113:93-95.
37. Hofmann WK, de Vos S, Tsukasaki K, Wachsman W, Pinkus GS, Said JW et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 2001;98:787-794.
38. Bartkova J, Lukas J, Strauss M, Bartek J. The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int J Cancer 1994;58:568-573.
39. Handa K, Yamakawa M, Takeda H, Kimura S, Takahashi T. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer 1999;84:225-233.
40. Liu JH, Yen CC, Lin YC, Gau JP, Yang MH, Chao TC et al. Overexpression of cyclin D1 in accelerated-phase chronic myeloid leukemia. Leuk Lymphoma 2004;45:2419-2425.
41. Hui P, Howe JG, Crouch J, Nimmakayalu M, Qumsiyeh MB, Tallini G et al. Real-time quantitative RT-PCR of cyclin D1 mRNA in mantle cell lymphoma: comparison with FISH and immunohistochemistry. Leuk Lymphoma 2003;44:1385-1394.
42. Steinman RA, Huang J, Yaroslavskiy B, Goff JP, Ball ED, Nguyen A. Regulation of p21 (WAF1) expression during normal myeloid differentiation. Blood 1998;91:4531-4542.